Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer
PaperCitations, authors & open-access status
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 115 citations, 2023 year and hybrid oa status.
115
Citations
2023
Year
hybrid
OA Status